Redx, the drug development company, is pleased to announce that it has identified a drug development candidate for its reversible Bruton’s tyrosine kinase (“BTK”) inhibitor program. The compound, named RXC005, has the potential to treat the majority of patients suffering from chronic lymphocytic leukaemia (“CLL”), including those who become resistant to the increasingly used treatment ibrutinib.
RXC005 is equally potent against the most common type of BTK protein implicated in CLL and the mutant BTK protein, which is currently estimated to be responsible for around 60% of the observed ibrutinib resistance. Redx’s BTK inhibitor could also offer a reduced side-effect profile compared to ibrutinib.
The Company will now progress studies to prepare the RXC005 program for first-in-human clinical trials. These trials are currently expected to commence in early 2018.
Dr Neil Murray, CEO of Redx, said:
“We’re delighted to announce another cancer drug candidate from our innovative development pipeline. The nomination of RXC005, a novel reversible BTK inhibitor, comes within a month of confirming the planned start of clinical trials for our most advanced program, the Porcupine inhibitor, in some hard-to-treat cancers.
“RXC005 has the potential to become a potent therapy for chronic lymphocytic leukaemia patients, including those resistant to ibrutinib treatment. We plan to initiate first-in-human studies for RXC005 early 2018.”